Search Results

CAY10602 5 mg  | 98.87%

TargetMol

CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate. Functional assays show that CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells, with approximately 75% inhibition achieved at 60 μM, without cytotoxicity.

More Information Supplier Page

CAY10602 50 mg  | 98.87%

TargetMol

CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate. Functional assays show that CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells, with approximately 75% inhibition achieved at 60 μM, without cytotoxicity.

More Information Supplier Page

ML329 5 mg  | Purity Not Available

TargetMol

ML329 is a small molecule inhibitor of MITF, inhibiting TRPM-1 promoter activity.

More Information Supplier Page

ML329 50 mg  | Purity Not Available

TargetMol

ML329 is a small molecule inhibitor of MITF, inhibiting TRPM-1 promoter activity.

More Information Supplier Page

ML329 25 mg  | Purity Not Available

TargetMol

ML329 is a small molecule inhibitor of MITF, inhibiting TRPM-1 promoter activity.

More Information Supplier Page

ML329 10 mg  | Purity Not Available

TargetMol

ML329 is a small molecule inhibitor of MITF, inhibiting TRPM-1 promoter activity.

More Information Supplier Page

AN2718 10 mg  | 98.89%

TargetMol

AN2718 is a benzoxaborole compound that displays broad antifungal effectiveness in vitro. It inhibits leucyl-tRN/A synthetase (LeuRS) from molds and yeasts (IC50s = 2 and 4.2 μM for A. fumigatus and C. albicans LeuRS, respectively), blocking protein synthesis.

More Information Supplier Page